Navigation Links
Pivotal Pulmonary Arterial Hypertension Study Published in The Lancet Concludes That Bosentan (Tracleer(R)) Demonstrates Benefits in Patients With Mildly Symptomatic WHO Functional Class II Disease
Date:6/20/2008

SOUTH SAN FRANCISCO, Calif. and ALLSCHWIL, Switzerland, June 20 /PRNewswire/ -- Actelion Ltd (SWX: ATLN) announced today that data published in The Lancet(1) show that, in mildly symptomatic pulmonary arterial hypertension (PAH) patients (WHO functional class II - WHO FC II), bosentan (Tracleer(R)) prevented clinical deterioration by significantly delaying time to clinical worsening and reduced the number of patients worsening to WHO FC III/IV. A significant reduction in pulmonary vascular resistance and a positive trend in increasing the 6MWD were also observed. The randomized, placebo-controlled EARLY (Endothelin Antagonist tRial in miLdlY symptomatic PAH patients) trial is the first and only trial conducted exclusively in a dedicated FC II PAH patient population.

Professor Nazzareno Galie of the University of Bologna, Italy and lead investigator commented: "The EARLY trial demonstrates that without treatment, even mildly symptomatic patients experience PAH progression within a short period of time. In contrast, treatment with bosentan significantly delayed PAH progression while improving hemodynamic parameters."

The findings of EARLY indicate that treatment with bosentan may be beneficial for WHO FC II PAH patients. Actelion is working with authorities in the US and Europe and in other countries worldwide to expand the label for Tracleer(R) to include WHO FC II.

EARLY is the third randomized controlled trial with bosentan, to provide data that show a consistent significant effect on delaying PAH progression and reducing disease severity. The data from the other two pivotal trials, Study 351(2) and BREATHE-1(3) trial, which both investigated bosentan in FC III and IV patients, were published in The Lancet and the New England Journal of Medicine respectively.

The objectives of the EARLY trial were to investigate the effects of bosentan specifically in PAH patients in WHO FC II and to gain more insight into early stage disease. The
'/>"/>

SOURCE Actelion Ltd
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Victory Pharma, Inc. Reports MGX006 Enters Into Pivotal Development Program
2. European Enrollment Begins in Pivotal Phase 3 Trial of Novel Combination Medicine Developed by Cogentus Pharmaceuticals
3. Medivation Initiates Second Pivotal Phase 3 Trial of Dimebon(TM) in Patients With Alzheimers Disease
4. Nephros Completes Pivotal U.S. Clinical Trial for its Hemodiafiltration Products
5. Auxilium Pharmaceuticals, Inc. Announces XIAFLEX(TM) Meets Primary Endpoint With Statistical Significance (p<0.001) in CORD I Pivotal Phase III Study for Dupuytrens Contracture
6. Vion Pharmaceuticals Announces Presentation of Interim Data from Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Acute Myelogenous Leukemia at the ASCO(R) Annual Meeting
7. NicOx Completes Patient Enrollment in Third Naproxcinod Pivotal Phase 3 Study
8. Impliant Restarts Pivotal Clinical Trial for Patented TOPS(TM) Spine System
9. Analysis of Ulcerative Colitis (UC) Time to Symptom Resolution Data from Pivotal Study of LIALDA(TM) (mesalamine) Presented at DDW
10. Delcath Updates Phase III Patient Enrollment as Pivotal Trial Accelerates, Durable Tumor Responses In Phase II Study Also Cited
11. Pivotal Study Shows Physician/Nurse Teams Using SEDASYS(TM) System Reduced Risk of Over Sedation With Propofol
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... , November 26, 2014 A ... of the organ protrudes through the wall of a weak ... area at birth are some of the causes of hernias. ... hiatal, femoral, and incisional. An inguinal hernia is when part ... umbilical hernia is found in the area of the umbilicus. ...
(Date:11/26/2014)...  CARsgen, a leader in the development of Chimeric ... variety of cancers, today announced the completion of a ... China -based healthcare private equity fund.   ... development of new therapeutics for liver, lung, stomach and ... Shanghai Renji Hospital, the company plans to initiate clinical ...
(Date:11/26/2014)... The medical magnetic resonance imaging (MRI) ... with world market revenues for 2013 at $5.1 ... types of medical imaging have led to improvements ... conditions in children and adults, each imaging procedure ... Medical Imaging Markets , analyzes the current and ...
Breaking Medicine Technology:Global Hernia Repair Devices Market Size, Share, Trends and Forecast 2014 to 2018 - Big Market Research 2Global Hernia Repair Devices Market Size, Share, Trends and Forecast 2014 to 2018 - Big Market Research 3Global Hernia Repair Devices Market Size, Share, Trends and Forecast 2014 to 2018 - Big Market Research 4CARsgen Completes Series A Financing 2Kalorama: Steady Growth in the Medical MRI Market 2Kalorama: Steady Growth in the Medical MRI Market 3
... Meeting of the Heart Failure Society of America (HFSA) will ... recent studies relating to heart failure. Dr. D.J. ... a recent study of heart failure patients who are hospitalized ... the heart, and the heart is unable to manage the ...
... the following update for its range of advanced wound care ... regulatory approvals and product listings, Innocoll has added six more ... and spray formats that are available for commercialization in the ... Zealand. These products include:   CollaCare®, a ...
Cached Medicine Technology:Studying Fluid Overflow in Patients With Devices 2Studying Fluid Overflow in Patients With Devices 3Innocoll Provides an Update on its Range of Advanced Wound Care and Related Collagen-based Products 2
(Date:11/28/2014)... PreDiabetes Centers , a ... employees learn their risk for type 2 diabetes ... a local school in partnership with the American ... , As the Presenting Sponsor for the ... is co-hosting diabetes-prevention presentations at Austin-area companies with ...
(Date:11/28/2014)... November 28, 2014 Mabel’s Labels ... kids lose® and an award-winning company established by four ... Cynthia Esp, and Tricia Mumby have been honored with ... recognized with the PROFIT Award for Excellence in Entrepreneurship. ... Esp, and Tricia Mumby) accepted the award on behalf ...
(Date:11/28/2014)... UniWigs.com, a leader in the wig industry, has announced a ... This promotion features: , > 400 pieces of ... off (no coupon code needed), > 10% off ... over $49 , Visit http://www.uniwigs.com for more details , ... Dec. 1st and the first 100 shoppers each day will receive ...
(Date:11/28/2014)... 28, 2014 "Most of my life, I ... use crutches," said an inventor from Findlay, Ohio. "I thought ... to support my foot, which inspired me to invent this ... a convenient way to support an injured foot. The sling ... eliminates the need for crutches. The design redistributes weight so ...
(Date:11/28/2014)... NEW ALBANY, IN (PRWEB) November 28, 2014 ... of Americans were already preparing for the Christmas shopping season. ... the best deals on Black Friday, the biggest retail shopping ... the latest gadget or electronic device, New Albany dentist ... gift options that can improve oral health and literally brighten ...
Breaking Medicine News(10 mins):Health News:PreDiabetes Centers Offers Workplace Diabetes Screening at Local School 2Health News:Mabel's Labels’ Co-Founders Named A Winner In The 2014 RBC Canadian Women Entrepreneur Awards Program; A Second-Time Win For The Brand 2Health News:Mabel's Labels’ Co-Founders Named A Winner In The 2014 RBC Canadian Women Entrepreneur Awards Program; A Second-Time Win For The Brand 3Health News:Pre-X'mas Crazy Sale Starts from $0 at UniWigs.com 2Health News:New Albany Dentist Offers Gift Ideas That Can Improve Oral Health 2Health News:New Albany Dentist Offers Gift Ideas That Can Improve Oral Health 3Health News:New Albany Dentist Offers Gift Ideas That Can Improve Oral Health 4
... celecoxib, known by its brand name Celebrex, can help prevent ... rectum and small intestine of children with an inheritable genetic ... rare but devastating disease, polyps begin forming in patients as ... hundreds or even thousands. The disease carries a 100-percent ...
... ... Programs, will unveil the Center for Biotechnology Education on Thursday, May 13, at ... the Montgomery County campus, 9601 Medical Center Drive in Rockville. , ... (PRWEB) May 13, 2010 -- The Johns Hopkins ...
... explanation for the persistent ability of melanoma cells to self-renew, ... of skin cancer. The concept of the "dynamic stemness" of ... tumor cells and cancer stem cells. The researchers write ... thatcontrary to other published reportsmelanoma does not appear to ...
... deletion syndrome (also known as DiGeorge syndrome) is ... an estimated incidence of at least one in ... severity but a multisystem impact, with symptoms that ... abnormalities, cleft palate, gastrointestinal problems, and neuropsychiatric abnormalities. ...
... ... Fellowship , ... May 12, 2010 -- University of Massachusetts Boston Chancellor J. Keith Motley today ... to fight against the HIV/AIDS epidemic, has been chosen as the recipient of the 2010 ...
... cells , THURSDAY, May 13 (HealthDay News) -- Researchers have ... cells in the laboratory that are similar to inner-ear cells ... , The cells in the inner ear have hair-like projections, ... are converted into a signal that can be interpreted in ...
Cached Medicine News:Health News:Johns Hopkins to Unveil Center for Biotechnology Education 2Health News:Johns Hopkins to Unveil Center for Biotechnology Education 3Health News:Wistar scientists explain the persistence of melanoma through 'dynamic stemness' 2Health News:Wistar scientists explain the persistence of melanoma through 'dynamic stemness' 3Health News:Without this protein, embryonic development halts 2Health News:Vietnamese Student Named UMass Boston JFK Award Winner 2Health News:Vietnamese Student Named UMass Boston JFK Award Winner 3Health News:Vietnamese Student Named UMass Boston JFK Award Winner 4Health News:Effort to Cure Some Types of Hearing Loss Gets Big Boost 2
Px2 thermal Cycler chassis (requires block). Multiple interchangeable blocks. Gradient capability. Adjustable height heated lid. Outstanding uniformity. Advanced control algorithms for reduced r...
... The Gene Cycler unit is an inexpensive personal ... for the PCR process. Lightweight, with a small ... almost anywhere, including the researcher's desk. , The ... researchers who do not have access to a ...
... Tetrad™ thermal cycler expands the envelope of ... cyler. It has four times the capacity ... providing very high throughput for laboratories that ... sequencing or diagnostic labs. Four blocks, ...
... Biosystems has designed its 60-well, 0.5 mL ... PCR applications (both DNA and RNA). The ... Frame ensure oil-free operation in the 0.5 ... the 0.5 mL GeneAmp PCR System 9700 ...
Medicine Products: